Core Insights - Oddity Tech Ltd. is set to release its quarterly earnings on November 19, 2025, with an expected EPS of $0.35 and revenue of approximately $145.47 million [1][6] Company Developments - The launch of Methodiq, a telehealth platform for medical skincare, signifies Oddity's strategic entry into the medical-grade skincare market, competing with companies like Hims [2][6] - Methodiq offers 28 new products targeting skin conditions such as acne and eczema, with prices ranging from $29 to $59, making them accessible to a broad audience [2] - The development of Methodiq took four years and integrates investments in biotechnology and AI-based computational imaging, allowing for online diagnosis and personalized treatments [3] Financial Performance - Oddity has a price-to-earnings (P/E) ratio of 18.89, indicating the market's valuation of its earnings [4][6] - The price-to-sales ratio stands at 2.76, reflecting investor willingness to pay per dollar of sales [4] - The enterprise value to sales ratio is 1.92, showing the company's total valuation relative to its sales [4] - The company maintains a low debt-to-equity ratio of 0.065, indicating conservative debt use [5] - A current ratio of 6.32 suggests strong liquidity, ensuring the company can cover short-term liabilities [5] - An earnings yield of 5.29% demonstrates Oddity's ability to generate earnings from each dollar invested [5]

Core Insights - Oddity, the parent company of Il Makiage, is launching Methodiq, a telehealth platform focused on medical-grade skin care, to compete with Hims and address issues in the medical care system [1][2] Company Overview - Methodiq has been in development for four years and offers 28 products targeting acne, hyperpigmentation, and eczema, with prices ranging from approximately $29 to $59 [1][2] - The platform combines investments in biotechnology, AI-based imaging, and digital retailing, aiming to capture a share of the medical skin care market projected to reach $113 billion in 2023 [2] Market Positioning - Methodiq directly competes with Hims, which has established a successful telehealth platform for anti-acne medications [2][4] - The launch indicates Oddity's potential for deeper expansion into the healthcare sector [2] User Base and Market Opportunity - Oddity has 60 million users, with around half experiencing skin conditions like acne and eczema, presenting a significant market opportunity [3][12] - There is a lack of dermatologists in over 60% of U.S. counties, highlighting the need for accessible dermatological care [13] Product Development and Technology - Methodiq utilizes AI and computational imaging technologies acquired through previous investments to enhance product offerings [7][8] - The platform includes a facial scan and a medical review process to recommend personalized treatment kits [9][14] Product Features - Methodiq's Clindalaq product combines prescription-strength ingredients with additional components to improve user experience and reduce side effects [10][11] - The platform aims to provide a "true beauty experience" in a prescription formula, making effective treatments more appealing [12] Access to Care - Methodiq seeks to improve access to dermatological care by connecting patients with medical professionals through a chat function, although it does not currently support video consultations [15][16] - The inclusion of various healthcare providers to prescribe treatments can enhance access to care, especially in underserved areas [17]